What can growth or venture debt be used for?

Growth debt can finance many of the same activities as equity: more time, product development, expansion, equipment, working capital or an acquisition. The important question is not whether a use is permitted in theory. It is whether that use creates a credible route to repay the loan.

Venture debt and growth credit are broad, overlapping forms of growth debt. No use case belongs exclusively to one label. The suitable structure depends on the company’s stage, cash profile, ownership, assets and the certainty of the investment.

Common use cases at a glance

Extending runway after an equity round

Runway is the period before a company is expected to run out of cash. Venture debt is commonly raised alongside or shortly after equity, when the company has fresh liquidity and investor support. The loan can add time to reach a revenue, product or regulatory milestone before the next equity round.

This can reduce dilution if the milestone supports a higher future valuation. It can also give the company a buffer when a financing process takes longer than expected.

The danger is treating debt as extra months without modelling the payments. Interest begins immediately in many facilities, and principal may start amortising before the next round. Amortisation is the scheduled repayment of the amount borrowed. The company should calculate monthly cash through the whole loan term under a delayed milestone and delayed fundraising case.

Debt is weakest as a last-minute bridge for an underperforming company with little cash and no committed equity. A hoped-for funding round is not a repayment plan.

Financing a product, R&D or regulatory milestone

A company may borrow to complete a product release, clinical study, certification, manufacturing step or other defined milestone. The case is strongest when the work is well scoped, the wider programme is funded and achieving the milestone is likely to improve revenue, financing options or company value.

Technical work is uncertain by nature. A founder should separate a delay from a failure. If the milestone takes six months longer, can the company still pay? If the outcome is negative, is there another product, funding source or route to repayment?

Very early research with an unknown commercial path is usually better suited to equity or grant funding. Some development institutions provide specialised venture debt for research-intensive companies, but they still apply eligibility and repayment tests.

Funding customer acquisition and commercial growth

Debt can fund sales hires, marketing or customer onboarding when the company already understands how spending turns into durable gross profit. It is less suitable for discovering whether a market exists.

A lender and management team should examine customer acquisition cost, gross margin, retention and payback period. Payback period means the time required for the gross profit from a customer to recover the cost of winning that customer.

The repayment timetable should follow the economics. If acquisition spending is recovered over 18 months but principal starts repaying after three months, the loan may create a cash squeeze even when the customers are valuable.

Working capital and contract delivery

Growth often consumes cash before it produces it. A company may need to pay staff, suppliers or manufacturers weeks or months before a customer pays. Debt can finance that working capital gap and allow the company to accept larger contracts without starving the rest of the business.

A general growth loan can do this, but invoice finance, receivables finance, inventory finance or a revolving facility may match the need more closely. A revolving facility allows the borrower to draw, repay and draw again within an agreed limit.

The lender will care about the customer’s ability to pay, contract terms, disputes, cancellations and concentration. A signed contract is not the same as collected cash. Model delays, partial delivery and customers using their right to withhold payment.

Geographic expansion and new teams

Growth debt can fund the cost of entering a new country, launching an adjacent product or building delivery capacity. It can be attractive when the company is applying a proven model and can stage spending as evidence appears.

The risk is assuming that a successful home market repeats automatically. Pricing, regulation, hiring, sales cycles and customer behaviour may differ. Later tranches tied to sensible milestones can reduce the amount borrowed before those assumptions are tested.

A tranche is one part of a facility made available separately. Check whether later tranches are committed when objective conditions are met or remain subject to lender discretion.

Equipment, facilities and other capital expenditure

Capital expenditure is spending on assets expected to be used over several years, such as laboratory equipment, manufacturing lines, servers or a new facility. Financing a long-lived asset can preserve cash for people and operations.

The most suitable product may be an equipment lease or asset finance rather than a general growth debt facility. An asset lender can size finance against equipment value and match payments to its useful life.

Specialist technology or medical equipment may have limited resale value despite its high purchase price. Installation delays, cost overruns and slower utilisation can also weaken the case. Test the cash benefit of the asset, not only its accounting life.

Acquisitions

Debt can help a growth company buy another business, product, team or technology without funding the entire price with new equity. It can also allow faster execution when a seller wants certainty.

The borrower needs a combined model, not simply the target’s historic accounts. Include purchase price, fees, working capital, integration costs, customer loss, duplicated roles and the timing of any savings. Synergies are benefits expected from combining the businesses; lenders will usually discount those that are uncertain or slow.

Acquisition debt can be appropriate for both venture debt and growth credit borrowers. The lender may base its decision on recurring revenue, earnings, company value, equity support or a mix. The product label does not determine the use.

Refinancing existing debt

A company may refinance to extend maturity, delay principal repayments, reduce cost, release restricted cash, consolidate several facilities or replace a lender whose mandate no longer fits.

The comparison should include arrangement and legal fees, early repayment charges, any warrant treatment and the new repayment profile. A lower interest margin may still produce a worse outcome if fees are large or principal is repaid faster.

Refinancing is constructive when it fixes a structural mismatch. It is dangerous when it only moves an unaffordable obligation into the future without changing the business or adding enough time to solve the problem.

Liquidity buffers and contingency capital

Some companies arrange a facility they do not expect to draw immediately. Availability can provide protection against collection delays, market disruption or a longer equity process. This is sometimes described as insurance capital.

Unused facilities may still carry commitment fees, and availability can expire. Later drawings may be conditional on company performance, minimum cash or the absence of a default. A £10 million headline facility is not a £10 million buffer if only £5 million is committed or the company cannot draw after a downturn.

Uses that deserve particular caution

• Covering recurring losses with no milestone, path to profitability or future financing plan.
• Repaying shareholders or funding distributions when the company still needs growth capital.
• Making a speculative acquisition outside the company’s operating experience.
• Funding an untested sales model with a payback period longer than the debt term.
• Using short-term debt for a long and uncertain research programme.
• Borrowing because equity valuation is disappointing, without proving that the company can repay.

A lender may permit some of these uses with specific controls, while another may prohibit them. The company should also ask whether the proposed use is sensible, not merely allowed.

A use-of-proceeds checklist

1. 1Define the precise activity, amount and timing rather than using a broad label such as “growth”.
2. 2Identify the measurable milestone or cash benefit the spending should produce.
3. 3Match drawdowns to when the money is needed; do not pay for unused debt without a reason.
4. 4Match repayment timing to the expected cash generation or financing event.
5. 5Model a downside case with slower revenue, higher costs and a delayed equity round.
6. 6Check that later tranches remain available in that downside case.
7. 7Compare the facility with a product designed for the asset or working capital need.
8. 8Confirm permitted uses, restrictions and reporting in the loan documents.
9. 9Protect enough cash to operate and respond if the investment underperforms.

The bottom line

Growth debt can extend runway, fund milestones, support sales, finance working capital, pay for equipment, enable expansion, fund acquisitions or refinance existing obligations.

Those uses are not exclusive to venture debt or growth credit. What changes with company stage is the evidence supporting repayment and the structure needed to protect cash.

A good use has a defined purpose, an observable result and a repayment route that survives delay. Debt should accelerate a credible plan, not hide the absence of one.

Where to go next

• When should a growth company use debt? tests whether debt is appropriate before a lender process begins.
• Growth debt vs equity compares dilution, repayment risk and strategic flexibility.
• Is your company suitable for growth lending? shows the features lenders look for in a suitable borrower.
• Growth debt repayment structures compares interest-only periods, amortisation and maturity structures.